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Abstract
© 2018 Petrov, Nikolsky and Masson. Neuromuscular junctions (NMJs) are directly involved into
such indispensable to life processes as respiration and locomotion. However, motor nerve forms
only one synaptic contact at each muscle fiber.  This unique configuration requires specific
properties and constrains to be effective.  The very high density of  acetylcholine receptors
(AChRs) of muscle type in synaptic cleft and an excess of acetylcholine (ACh) released under
physiological conditions make this synapse extremely reliable. Nevertheless, under pathological
conditions such as myasthenia gravis and congenital myasthenic syndromes, the safety factor
can be markedly reduced. Drugs used for short-term symptomatic therapy of these pathological
states, cause partial inhibition of cholinesterases (ChEs). These enzymes catalyze the hydrolysis
of  ACh,  thus  terminate  its  action  on  AChRs.  Extension  of  the  lifetime  of  ACh  molecules
compensates muscular AChRs abnormalities and, consequently, rescues muscle contractions. In
this mini review, we will first outline the functional organization of the NMJ, and then, consider
the concept of the safety factor and how it may be changed. This will be followed by a look at
autoregulation of ACh release that influences the safety factor of NMJs. Finally, we will consider
the  morphological  features  of  NMJs  as  a  putative  reserve  to  increase  effectiveness  of
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